124O - Stereotactic ablative body radiotherapy (SABR) with flattening filter free (FFF) mode for NSCLC oligometastatic patients: feasibility and outcomes

Date 28 March 2014
Event ELCC 2014
Session Proffered papers 4 - SCLC and locally advanced NSCLC
Topics Non-Small-Cell Lung Cancer, Locally Advanced
Surgery and/or Radiotherapy of Cancer
Presenter Fiorenza De Rose
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors P. Navarria1, F. De Rose2, A.M. Ascolese1, E. Clerici1, A. Tozzi1, A. Fogliata3, P. Mancosu1, A. Gaudino1, L. Cozzi3, M. Scorsetti1
  • 1Radiotherapy And Radiosurgery, Humanitas Research Hospital, 20089 - Rozzano/IT
  • 2Radiotherapy And Radiosurgery, Humanitas research hospital, 20089 - Rozzano/IT
  • 3Physics, IOSI, 6500 - Bellinzona/CH


Data in the literature suggest the existence of oligometastatic disease, a state in which metastases are limited in number and site. Different kinds of local therapies have been used for the treatment of limited metastases and in the recent years reports on the use of Stereotactic Ablative radiotherapy (SABR) are emerging and the early results on local control are promising. The aim of this study is the evaluation of local control, toxicity and overall survival in NSCLC oligometastatic patients underwent SABR